3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Lymphoid
1
Conditions
Severe Acute Respiratory Syndrome
1
Pneumonia
1
Lymphoma, Follicular
1
COVID-19
1
Interventions
Hydroxychloroquine
4
Standard of Care
2
Sodium Chloride
2
COH04S1 COVID-19 vaccine
2
BNT162 Vaccine
2
Azithromycin
2
tocilizumab
1
palbociclib
1
ogalvibart
1
monalizumab
1
crexavibart
1
cilgavimab and tixagevimab drug combination
1
avdoralimab
1
XAV-19
1
Specimen Handling
1
Radiotherapy
1
Medical Marijuana
1
Losartan
1
Janus Kinase Inhibitors
1
Ivermectin
1
Interleukin-7
1
HuMax-IL8
1
Gelsolin
1
CVnCoV COVID-19 vaccine
1
COVID-19 Vaccines
1
2019-nCoV Vaccine mRNA-1273
1
11-(2-pyrrolidin-1-ylethoxy)-14,19-dioxa-5,7,26-triazatetracyclo(19.3.1.1(2,6).1(8,12))heptacosa-1(25),2(26),3,5,8,10,12(27),16,21,23-decaene
1
1-palmityl-2-(4-carboxybutyl)-sn-glycero-3-phosphocholine
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 2
×
COVID-19
×
XAV-19
×
Clear all
NCT04453384
2022-03-25
POLYCOR
Nantes University Hospital
Phase 2
Completed
416 enrolled